A new study has unveiled a promising adjuvant therapy regimen that significantly improves patient outcomes in hepatocellular carcinoma (HCC). Published in JAMA Surgery , the study sheds light on the efficacy and safety of combining sorafenib and transarterial chemoembolisation (TACE) as post-operative adjuvant therapy for patients with HCC and portal vein tumour thrombus (PVTT).
HCC poses a formidable challenge in oncology, with a significant proportion of patients diagnosed at advanced stages, leading to poor prognosis. Particularly concerning is the subgroup of patients with PVTT, accounting for a substantial portion of cases and facing dismal survival rates despite current treatment modalities.
Current first-line treatments for HCC with PVTT primarily revolve around systemic therapy, including anti-vascular endothelial growth factor receptor agents such as sorafenib and lenvatinib, or monoclonal antibodies like bevacizumab plus atezolizumab. However, while these therapies offer some survival benefits, the median overall survival and progression-free survival remain far from satisfactory, underscoring the urgent need for more effective interventions.
Recognizing the pressing need to improve outcomes for patients with HCC and PVTT, researchers explored novel therapeutic avenues. The study aimed to evaluate the efficacy and safety of the sorafenib and TACE, combination as adjuvant therapy following hepatectomy.
Conducted as a phase 3, open-label, multicenter, randomised clinical trial in China, the study enrolled a total of 158 patients with resectable HCC and PVTT. Patients were randomly assigned to receive either sorafenib plus TACE or sorafenib alone as postoperative adjuvant therapy.
All patients in the transarterial chemoembolisation with sorafenib group successfully underwent 1 session of transarterial chemoembolisation and the technical success rate was 100%. Patients receiving sorafenib plus TACE demonstrated significantly longer recurrence-free survival and overall survival compared to those receiving sorafenib alone. The 2-year recurrence-free survival rate in the transarterial chemoembolization with sorafenib group was 43% and the sorafenib group 21%, (P = .002)
The combination therapy not only extended survival but also exhibited a favourable safety profile, with no significant increase in adverse events compared to sorafenib monotherapy.
The findings of this study hold profound implications for clinical practice, offering a beacon of hope for patients grappling with HCC and PVTT. The combination of sorafenib and TACE represents a promising avenue for enhancing survival outcomes and improving the quality of life for these patients.
While the study marks a significant milestone in HCC treatment, further research is warranted to validate and refine the findings. Additionally, efforts to elucidate optimal patient selection criteria and treatment protocols will be crucial in maximising the therapeutic potential of sorafenib plus TACE.
